02:37 PM EDT, 03/18/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) shares were down nearly 23% in recent Tuesday trading after the biopharmaceutical company said a young patient with Duchenne muscular dystrophy passed away due to acute liver failure following treatment with its Elevidys gene therapy.

Acute liver injury, including failure, is a known side effect of Elevidys and other adeno-associated viruses-based gene therapies, though this level of severity was not previously reported, the company said.

The patient had a recent cytomegalovirus infection, which may have contributed to the liver damage, Sarepta Therapeutics ( SRPT ) said.

The company said it is continuing its investigation into the incident, has informed health authorities, and will update the prescribing information.

Price: 76.80, Change: -24.55, Percent Change: -24.22